NDAOPHTHALMICSOLUTION/DROPS
Approved
Oct 2021
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
4/8 — Partial
VUITY (pilocarpine hydrochloride) by AbbVie is clinical pharmacology: pharmacodynamics: pilocarpine is a cholinergic parasympathomimetic agent exerting a broad spectrum of pharmacologic effects with predominant muscarinic action. First approved in 2021.
Drug data last refreshed 13h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VUITY (pilocarpine hydrochloride) is a cholinergic parasympathomimetic agent administered as an ophthalmic solution for presbyopia, stimulating accommodation through muscarinic agonism. It works by increasing ciliary muscle contraction to improve near vision focus in aging eyes. The drug represents a novel non-surgical approach to age-related accommodation loss in a large, underserved patient population.
$0.283MPart D
Peak12.6 years to LOEEarly-stage ophthalmic product in peak commercialization phase with modest Part D volume suggesting significant growth runway as awareness builds in the presbyopia market.
Mechanism of Action
CLINICAL PHARMACOLOGY: Pharmacodynamics: Pilocarpine is a cholinergic parasympathomimetic agent exerting a broad spectrum of pharmacologic effects with predominant muscarinic action. Pilocarpine, in appropriate dosage, can increase secretion by the exocrine glands. The sweat, salivary, lacrimal,…
Worked on VUITY at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.